Archivio

🇬🇧 Easy-to-take medicine better at suppressing HIV in children

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Once-daily DTG more effective in treating HIV in children

Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1

Ethical youth engagement in the HIV response

Dolutegravir-based ART is superior to standard of care ART in young children <14kg living with HIV

Diaskin and tuberculin skin test as tuberculosis diagnostics in Russian children: comparative observational study

REACH project published in CORDIS

Characterisation of the HIV proviral and inducible reservoir in well- suppressed children on long-term ART

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

World AIDS Day 2021: How paediatric HIV has changed in the last 30 years

NeoVanc: New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis

🇬🇧 NeoVanc: New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis

Public consultation on the draft WHO Essential Medicines List Antibiotic Book

In Memory of Dr Scott M. Hammer

🇬🇧 VERDI project launches

World Pneumonia Day 2021: Every breath counts

ODYSSEY trial wins 2021 Hector Award